By investing across public and private markets, Foresite creates a positive feedback loop. Understanding what public investors value (e.g., product-centric assets for unmet needs like pancreatic cancer) directly influences the firm's strategy for incubating and building new companies from scratch.

By offering lab space and operational support first, Mission Bio Capital establishes relationships with founders by solving their immediate problems. This transforms the traditional power dynamic from a 'begging for money' pitch to a partnership, where capital becomes a natural extension of an already collaborative relationship.

M13 was built to be a different kind of VC by operating like a tech company. With a team of mostly former operators, they focus on building an institutionalized platform with KPIs and vision statements. The primary job is seen as building the firm, with investing as the secondary function.

Instead of passively waiting for pitches, proactive VCs like Foresight Capital build new companies by acquiring promising assets. They actively source clinical or later-stage assets, particularly from Asia where market dynamics are favorable, and then build a new company around them with a proven entrepreneur from their network.

Top VCs are reviving the early, hands-on model of pioneers like Arthur Rock. Instead of just investing, firms are co-designing new labs from scratch, providing compute, capital, and commercial guidance. This "company creation" approach is viable again as capital is no longer the primary bottleneck for ambitious, frontier-tech ideas.

Beyond accelerators, pure investors, and traditional company builders, this new VC model provides "hardcore primary data generation drug making support." It involves a team of 10+ experts engaging with a startup multiple times per day, offering an intensity of operational involvement that other models lack.

A direct path to venture capital in biotech is less effective than one that includes deep operational experience. Gaining experience in research, business development, commercial, and startup C-suite roles provides the credibility and understanding to "speak eye to eye" with portfolio companies and become a much better investor.

WonderCo first maps a target market to find an exceptional company to back. They only choose to incubate a new company from scratch if their deep search reveals no existing "rocket" to provide fuel for, ensuring they build from a position of unique market insight.

Unlike venture creation firms that generate ideas internally, Curie.bio operates on a 'Freedom for Founders' principle. It believes the best ideas come from external innovators and its role is to augment them with capital-efficient support, fractional expertise, and operational help to translate those ideas into companies.